Peroxisome proliferator-activated receptor δ regulates inflammation via NF-κB signaling in polymicrobial sepsis

American Journal of Pathology

Volumn 177, Issue 4, 2010, Pages 1834-1847

  Zingarelli, Basilia ^a   Piraino, Giovanna ^a   Hake, Paul W ^a   O'Connor, Michael ^a   Denenberg, Alvin ^a   Fan, Hongkuan ^b   Cook, James A ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; INFLAMMATION; MACROPHAGE; MALE; MIXED INFECTION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FUNCTION; SEPSIS; SIGNAL TRANSDUCTION;

EID: 77957348621     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.091010     Document Type: Article

References (42)

1. Remick DG: Pathophysiology of sepsis. Am J Pathol 2007, 170:1435-1444
2. Medzhitov R, Janeway C Jr: Innate immune recognition: mechanisms and pathways. Immunol Rev 2000, 173:89-97
3. Baeuerle PA: IκB-NF-κB structures: at the interface of inflammation control. Cell 1998, 11:729-731
4. Zingarelli B, Sheehan M, Wong HR: Nuclear factor-κB as a therapeutic target in critical care medicine. Crit Care Med 2003, 31:S105-S111
5. Brown JD, Plutzky J: Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007, 115:518-533
6. Karpe F, Ehrenborg EE: PPARδ in humans: genetic and pharmacological evidence for a significant metabolic function. Curr Opin Lipidol 2009, 20:333-336
7. Leibowitz MD, Fiévet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera J, Cullinan CA, Sparrow CP, Baffic J, Berger GD, Santini C, Marquis RW, Tolman RL, Smith RG, Moller DE, Auwerx J: Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Lett 2000, 473:333-336
8. Oliver WRJr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM: A selective peroxisome proliferator- activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001, 98:5306-5311
9. Berger JP, Akiyama TE, Meinke PT: PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005, 26:244-251
10. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM: Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 2003, 113:159-170
11. Michalik L, Wahli W: Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest 2006, 116:598-606
12. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver WRJr, Sternbach DD: Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)-synthesis and biological activity. Bioorg Med Chem Lett 2003, 13:1517-1521
13. Rival Y, Beneteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau JF, Junquero D, Colpaert FC, Delhon A: PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 2002, 435:143-151
14. Ding G, Cheng L, Qin Q, Frontin S, Yang Q: PPARδ modulates lipopolysaccharide-induced TNFα inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol 2006, 40:821-828
15. Fan Y, Wang Y, Tang Z, Zhang H, Qin X, Zhu Y, Guan Y, Wang X, Staels B, Chien S, Wang N: Suppression of pro-inflammatory adhesion molecules by PPAR-δ in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 2008, 28:315-321
16. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM: Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 1997, 276:589-592
17. 12,14-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 2003, 171:6827-6837
18. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, Evans RM: Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 2002, 99:303-308
19. Wahl C, Liptay S, Adler G, Schmid RM: Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998, 101:1163-1174
20. Rittirsch D, Hoesel LM, Ward PA: The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 2007, 81:137-143
21. Cavaillon JM, Adib-Conquy M: Monocytes/macrophages and sepsis. Crit Care Med 2005, 33:S506-S509
22. Peters JM, Lee SS, Li W, War JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, Gonzalez FJ: Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator- activated receptor β(δ). Mol Cell Biol 2000, 20:5119-5128
23. Juge-Aubry C, Pernin A, Favez T, Burger AG, Wahli W, Meier CA, Desvergne B: DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5′-flanking region. J Biol Chem 1997, 272:25252-25259
24. Drouet C, Shakhov AN, Jongeneel CV: Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor-α promoter in primary macrophages. J Immunol 1991, 147:1694-1700
25. Kim MS, Sweeney TR, Shigenaga JK, Chui LG, Moser A, Grunfeld C, Feingold KR: Tumor necrosis factor and interleukin 1 decrease RXRα. PPARα, PPARγ, LXRα, and the coactivators SRC-1, PGC-1α, and PGC-1β in liver cells. Metabolism 2007, 256:267-279
26. Feingold K, Kim MS, Shigenaga J, Moser A, Grunfeld C: Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am J Physiol Endocrinol Metab 2004, 286:E201-E207
27. Cimini A, Bernardo A, Cifone MG, Di Marzio L, Di Loreto S: TNFα downregulates PPARδ expression in oligodendrocyte progenitor cells: implications for demyelinating diseases. Glia 2003, 41:3-14
28. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, Curtiss LK: Transcriptional repression of atherogenic inflammation: modulation by PPARδ. Science 2003, 302:453-457
29. Lee CH, Kang K, Mehl IR, Nofsinger R, Alaynick WA, Chong LW, Rosenfeld JM, Evans RM: Peroxisome proliferator-activated receptor δ promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage. Proc Natl Acad Sci USA 2006, 103:2434-2439
30. -/- mice. Atherosclerosis 2005, 181:29-37
31. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK: PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages. Proc Natl Acad Sci USA 2003, 100:6712-6717
32. Sheehan M, Wong HR, Hake PW, Zingarelli B: Parthenolide improves systemic hemodynamics and decreases tissue leukosequestration in rats with polymicrobial sepsis. Crit Care Med 2003, 31:2263-2270
33. Arnalich F, Garcia-Palomero E, Lopez J, Jimenez M, Madero R, Renart J, Vazquez JJ, Montiel C: Predictive value of nuclear factor κB activity and plasma cytokine levels in patients with sepsis. Infect Immun 2000, 68:1942-1945
34. Paterson RL, Galley HF, Dhillon JK, Webster NR: Increased nuclear factor κB activation in critically ill patients who die. Crit Care Med 2000, 28:1047-1051
35. Zanotti S, Kumar A, Kumar A: Cytokine modulation in sepsis and septic shock. Expert Opin Investig Drugs 2002, 11:1061-1075
36. Shi Y, Hon M, Evans RM: The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci USA 2002, 99:2613-2618
37. Tsai EY, Falvo JV, Tsytsykova AV, Barczak AK, Reimold AM, Glimcher LH, Fenton MJ, Gordon DC, Dunn IF, Goldfeld AE: A lipopolysaccharide- specific enhancer complex involving Ets, Elk-1, Sp1, and CREB binding protein and p300 is recruited to the tumor necrosis factor alpha promoter in vivo. Mol Cell Biol 2000, 20:6084-6094
38. Yao J, Mackman N, Edgington TS, Fan ST: Lipopolysaccharide induction of the tumor necrosis factor-α promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-κB transcription factors. J Biol Chem 1997, 272:17795-17801
39. 2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARβ and the proto-oncogene BCL-6. Mol Cell Biol 2007, 27:8374-8387
40. Westergaard M, Henningsen J, Johansen C, Rasmussen S, Svendsen ML, Jensen UB, Schr¿der HD, Staels B, Iversen L, Bolund L, Kragballe K, Kristiansen K: Expression and localization of peroxisome proliferator-activated receptors and nuclear factor κB in normal and lesional psoriatic skin. J Investig Dermatol 2003, 121:1104-1117
41. Takata Y, Liu J, Yin F, Collins AR, Lyon CJ, Lee CH, Atkins AR, Downes M, Barish GD, Evans RM, Hsueh WA, Tangirala RK: PPARδ-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci USA 2008, 105:4277-4282
42. Barish GD, Atkins AR, Downes M, Olson P, Chong LW, Nelson M, Zou Y, Hwang H, Kang H, Curtiss L, Evans RM, Lee CH: PPARδ regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci USA 2008, 105:4271-4276